Roman Shimanovich
Overview
Explore the profile of Roman Shimanovich including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
162
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Butler J, Rescourio G, Milgram B, Foti R, Kornecook T, Ligutti J, et al.
Bioorg Med Chem Lett
. 2022 Jul;
73:128892.
PMID: 35850422
Na1.7 is an actively pursued, genetically validated, target for pain. Recently reported quinolinone sulfonamide inhibitors displayed promising selectivity profiles as well as efficacy in preclinical pain models; however, concerns about...
2.
Saenz S, Local A, Carr T, Shakya A, Koul S, Hu H, et al.
PLoS One
. 2021 Nov;
16(11):e0248034.
PMID: 34752458
Retinoic acid receptor-related orphan nuclear receptor (ROR) γt is a member of the RORC nuclear hormone receptor family of transcription factors. RORγt functions as a critical regulator of thymopoiesis and...
3.
Agarwal P, Greene D, Sherman S, Wendl K, Vega L, Park H, et al.
Eur J Pharm Sci
. 2020 Dec;
158:105689.
PMID: 33359482
Sustained-release formulations are important tools to convert efficacious molecules into therapeutic products. Hydrogels enable the rapid assessment of sustained-release strategies, which are important during preclinical development where drug quantities are...
4.
Graceffa R, Boezio A, Able J, Altmann S, Berry L, Boezio C, et al.
J Med Chem
. 2017 Mar;
60(14):5990-6017.
PMID: 28324649
Because of its strong genetic validation, Na1.7 has attracted significant interest as a target for the treatment of pain. We have previously reported on a number of structurally distinct bicyclic...
5.
Boezio A, Copeland K, Rex K, Albrecht B, Bauer D, Bellon S, et al.
J Med Chem
. 2016 Jan;
59(6):2328-42.
PMID: 26812066
Deregulation of the receptor tyrosine kinase mesenchymal epithelial transition factor (MET) has been implicated in several human cancers and is an attractive target for small molecule drug discovery. Herein, we...
6.
Peterson E, Teffera Y, Albrecht B, Bauer D, Bellon S, Boezio A, et al.
J Med Chem
. 2015 Apr;
58(9):4087.
PMID: 25901648
No abstract available.
7.
Peterson E, Teffera Y, Albrecht B, Bauer D, Bellon S, Boezio A, et al.
J Med Chem
. 2015 Feb;
58(5):2417-30.
PMID: 25699405
The overexpression of c-Met and/or hepatocyte growth factor (HGF), the amplification of the MET gene, and mutations in the c-Met kinase domain can activate signaling pathways that contribute to cancer...
8.
Kleinman M, Baertschi S, Alsante K, Reid D, Mowery M, Shimanovich R, et al.
Mol Pharm
. 2014 Nov;
11(11):4179-88.
PMID: 25364862
Zeneth is a new software application capable of predicting degradation products derived from small molecule active pharmaceutical ingredients. This study was aimed at understanding the current status of Zeneth's predictive...
9.
Shimanovich R, Cooke M, Peterson M
J Pharm Sci
. 2012 Jul;
101(10):4013-7.
PMID: 22777723
Pharmaceutical hydrates have been used as clinical development candidates and in marketed products. The physical stability of hydrates can pose unique challenges to their development because of their particular sensitivity...
10.
Boezio A, Berry L, Albrecht B, Bauer D, Bellon S, Bode C, et al.
Bioorg Med Chem Lett
. 2009 Oct;
19(22):6307-12.
PMID: 19819693
Deregulation of the receptor tyrosine kinase c-Met has been implicated in several human cancers and is an attractive target for small molecule drug discovery. We previously showed that O-linked triazolopyridazines...